

Vaccine Fact Sheet: MenB



Topic	Bexsero®	Trumenba®
Manufacturer	GSK Detailed Prescribing Information	Pfizer Detailed Prescribing Information
Protects Against	Invasive meningococcal disease caused by <i>N. meningitidis</i> serogroup B	Invasive meningococcal disease caused by <i>N. meningitidis</i> serogroup B
Approved Ages	Persons aged 10 through 25 years old	Persons aged 10 through 25 years old
CDPH Immunization Program Offering Product		
Routine schedule¹	Children: Routine Risk: Two-dose series ≥ 6 months apart at age 16-18*; use shared clinical decision-making. High Risk: Three-dose series at 0, 1-2, and 6 months (minimum age 10 years) Adults: Routine Risk: Two-dose series ≥ 6 months apart through age 23*; use shared clinical decision-making. High Risk: Three-dose series 0, 1-2, and 6 months *To optimize rapid protection (e.g., for students starting college in less than 6 months), a 3-dose series (0, 1–2, 6 months) may be administered. Refer to: CDPH Meningococcal Vaccine Timing Guides: Routine Risk or High Risk	Children: Routine Risk: Two-dose series ≥ 6 months apart at age 16-18*; use shared clinical decision-making. High Risk: Three-dose series at 0, 1-2, and 6 months (minimum age 10 years) Adults: Routine Risk: Two-dose series ≥ 6 months through age 23*; use shared clinical decision-making. High Risk: Three-dose series 0, 1-2, and 6 months *To optimize rapid protection (e.g., for students starting college in less than 6 months), a 3-dose series (0, 1–2, 6 months) may be administered. Refer to: CDPH Meningococcal Vaccine Timing Guides: Routine Risk or High Risk
Minimum Intervals	2-dose schedule: 6-month minimum interval between dose 1 and 2. 3-dose schedule: 1-month minimum interval between dose 1 and 2, 4-month minimum interval between dose 2 and 3, 6-month minimum interval between dose 1 and 3.	2-dose schedule: 6-month minimum interval between dose 1 and 2. 3-dose schedule: 1-month minimum interval between dose 1 and 2, 4-month minimum interval between dose 2 and 3, 6-month minimum interval between dose 1 and 3.
Administration	Intramuscular (IM) injection	Intramuscular (IM) injection

Vaccine Fact Sheet: MenB (Continued)

Topic	Bexsero®	Trumenba®
Packaging	Vaccine is packaged as: -10 single-dose 0.5mL syringes, OR -1 single-dose 0.5mL syringe per carton	Vaccine is packaged as: -10 single-dose 0.5mL syringes, OR -5 single-dose 0.5mL syringes
Storage	Refrigerate between 36°F and 46°F (2°C to 8°C) Do not freeze	Refrigerate between 36°F and 46°F (2°C to 8°C) Do not freeze
Full ACIP Recommendations	ACIP Meningococcal Vaccine Recommendations	ACIP Meningococcal Vaccine Recommendations
VFC Letter	VFC MenB Vaccine Clinical Letter	VFC MenB Vaccine Clinical Letter
Billing Codes	CPT code for vaccine: 90620 CPT code for administration: 90640 Medical Fee-For-Service (FFS) administration for VFC supplied vaccine: 90620-SL (for ages 16 through 18 years); 90620-SL and –SK for high risk persons 10 through 15 years). ICD-10-CM code (encounter for immunization): Z23	CPT code for vaccine: 90620 CPT code for administration: 90640 Medical Fee-For-Service (FFS) administration for VFC supplied vaccine: 90620-SL (for ages 16 through 18 years); 90620-SL and –SK for high risk persons 10 through 15 years). ICD-10-CM code (encounter for immunization): Z23
Comments	Licensed in 2015	Licensed in 2014

¹ MenB vaccine brands are not interchangeable.

Refer to [Vaccine Fact Sheets](https://www.eziz.org/Resources/VaccineFactSheets) (EZIZ.org/Resources/VaccineFactSheets).